These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11255447)

  • 21. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study.
    Waring SC; Rocca WA; Petersen RC; O'Brien PC; Tangalos EG; Kokmen E
    Neurology; 1999 Mar; 52(5):965-70. PubMed ID: 10102413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States).
    Green PK; Weiss NS; McKnight B; Voigt LF; Beresford SA
    Cancer Causes Control; 1996 Nov; 7(6):575-80. PubMed ID: 8932917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
    Renoux C; Dell'aniello S; Garbe E; Suissa S
    BMJ; 2010 Jun; 340():c2519. PubMed ID: 20525678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease.
    Greene RA
    Int J Fertil Womens Med; 2000; 45(4):253-7. PubMed ID: 10997480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women.
    Rossi R; Bursi F; Veronesi B; Cagnacci A; Modena MG
    Maturitas; 2004 Dec; 49(4):315-20. PubMed ID: 15531127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of estrogen and progestin replacement on arterial stiffness indices in postmenopausal women.
    Scuteri A; Lakatta EG; Bos AJ; Fleg JL
    Aging (Milano); 2001 Apr; 13(2):122-30. PubMed ID: 11405385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.
    Grodstein F; Stampfer MJ; Manson JE; Colditz GA; Willett WC; Rosner B; Speizer FE; Hennekens CH
    N Engl J Med; 1996 Aug; 335(7):453-61. PubMed ID: 8672166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of endometrial cancer following estrogen replacement with and without progestins.
    Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
    J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a population-based case-control study.
    Tetsche MS; Jacobsen J; Nørgaard M; Baron JA; Sørensen HT
    Am J Gastroenterol; 2007 Feb; 102(2):275-8. PubMed ID: 17311649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormone therapy and ovarian cancer.
    Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
    JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced mortality associated with long-term postmenopausal estrogen therapy.
    Ettinger B; Friedman GD; Bush T; Quesenberry CP
    Obstet Gynecol; 1996 Jan; 87(1):6-12. PubMed ID: 8532268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmenopausal estrogen use affects risk for Parkinson disease.
    Currie LJ; Harrison MB; Trugman JM; Bennett JP; Wooten GF
    Arch Neurol; 2004 Jun; 61(6):886-8. PubMed ID: 15210525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism.
    Renoux C; Dell'Aniello S; Brenner B; Suissa S
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):554-560. PubMed ID: 28326633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen.
    Canonico M; Carcaillon L; Plu-Bureau G; Oger E; Singh-Manoux A; Tubert-Bitter P; Elbaz A; Scarabin PY
    Stroke; 2016 Jul; 47(7):1734-41. PubMed ID: 27256671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Links between hormone replacement therapy and neoplasia.
    Hulka BS
    Fertil Steril; 1994 Dec; 62(6 Suppl 2):168S-175S. PubMed ID: 7958013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
    Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
    Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy.
    Heckbert SR; Kaplan RC; Weiss NS; Psaty BM; Lin D; Furberg CD; Starr JR; Anderson GD; LaCroix AZ
    Arch Intern Med; 2001 Jul; 161(14):1709-13. PubMed ID: 11485503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study.
    Jonas HA; Kronmal RA; Psaty BM; Manolio TA; Meilahn EN; Tell GS; Tracy RP; Robbins JA; Anton-Culver H
    Ann Epidemiol; 1996 Jul; 6(4):314-23. PubMed ID: 8876842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings.
    Roberts RO; Cha RH; Knopman DS; Petersen RC; Rocca WA
    Alzheimer Dis Assoc Disord; 2006; 20(3):141-6. PubMed ID: 16917183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.